Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics
MWN-AI** Summary
Horizon Technology Finance Corporation (NASDAQ: HRZN) has made headlines by providing a $50 million venture loan facility to Pelthos Therapeutics Inc. (NYSE American: PTHS), with an initial disbursement of $30 million and the remaining $20 million earmarked for future growth initiatives. Pelthos, a biopharmaceutical enterprise, specializes in the commercialization of innovative dermatological treatments, notably ZELSUVMI™ (berdazimer), an FDA-approved topical gel for molluscum contagiosum. This common skin infection is characterized by small bumps or lesions, and ZELSUVMI leverages the Nitricil platform to deliver nitric oxide directly to affected areas efficiently and safely.
Recently, Pelthos expanded its portfolio by acquiring rights to additional products, including Xepi® Cream for impetigo and Xeglyze® for head lice. The funding from Horizon aims to bolster Pelthos' working capital and facilitate general growth. Paul Seitz, Chief Investment Officer at Horizon, expressed optimism about Pelthos’ innovation in dermatology, emphasizing ZELSUVMI as a valuable at-home treatment option.
Scott Plesha, CEO of Pelthos, praised Horizon's expertise in structuring financing tailored to meet their growth strategy, highlighting how this loan facility will be critical in promoting ZELSUVMI and Xepi Cream within pediatric and dermatologic circles while also scaling business operations, including the launch of Xeglyze.
Horizon Technology Finance Corporation, externally managed by an affiliate of Monroe Capital, operates as a leading specialty finance company providing secured loans primarily to venture-capital backed companies in technology, life sciences, healthcare, and sustainability sectors. With this strategic investment, both companies aim for significant growth potential in the burgeoning biopharmaceutical market.
MWN-AI** Analysis
Horizon Technology Finance's recent $50 million venture loan facility to Pelthos Therapeutics highlights a notable opportunity within the biopharmaceutical sector, particularly in dermatology treatments. While the initial $30 million provides immediate capital to support commercialization efforts for Pelthos’s FDA-approved ZELSUVMI™, additional funding earmarked for future growth could pave the way for substantial revenue increases.
Investors should consider the strategic positioning of Pelthos. With a focus on treating molluscum contagiosum through ZELSUVMI™, Pelthos is tapping into a persistent market need for effective at-home treatment options, enhancing patient accessibility and compliance. Furthermore, the recent acquisition of Xepi® Cream and Xeglyze® provides a diversified product portfolio that enhances their market footprint.
Additionally, the backing from Horizon Technology Finance, known for its specialization in life sciences and venture lending, underscores confidence in Pelthos’s growth potential. The financial support not only alleviates immediate cash requirements but also suggests that Pelthos has a solid growth trajectory in operational scaling and market penetration.
From an investment perspective, Pelthos presents a compelling case given its innovative products and the financial muscle from Horizon. The company is poised to capture significant market share, especially within pediatric and dermatologic communities, bolstered by targeted marketing and distribution strategies for its products.
However, it is vital to remain aware of potential risks, including regulatory hurdles and market competition. Therefore, investors should conduct thorough due diligence on both Pelthos’s product pipeline and broader industry trends. For those with a higher risk tolerance, acquiring Pelthos stock could present an appealing opportunity in a burgeoning sector. As always, diversifying investments and monitoring market developments will be key in navigating this promising landscape.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon”) (the “Company”), an affiliate of Monroe Capital, today announced it has provided a $50 million venture loan facility to Pelthos Therapeutics Inc. (NYSE American: PTHS) (“Pelthos”), with an initial funding of $30 million, and up to $20 million to support future growth.
Pelthos is a publicly traded biopharmaceutical company that is licensed to commercialize ZELSUVMI™ (berdazimer) topical gel, an FDA-approved treatment of molluscum contagiosum, a common skin infection characterized by small bumps or lesions. ZELSUVMI delivers nitric oxide directly to the affected skin or tissue via the Nitricil platform, which enables the gel to slowly and safely release onto the affected areas. Recently, Pelthos also acquired the rights to Xepi® Cream, a topical treatment for impetigo, and Xeglyze®, a topical treatment for head lice. The loan proceeds will be used for working capital and general growth purposes.
“Pelthos is bringing meaningful innovation to the dermatology space,” said Paul Seitz, Chief Investment Officer of Horizon. “ZELSUVMI offers a new at-home option for individuals with molluscum contagiosum, providing an alternative to traditional in-office procedures. We are excited to support this treatment and Pelthos’ continued growth.”
“With extensive experience lending to high-quality life science companies, Horizon was able to structure a financing facility that aligned with our current growth strategy,” said Scott Plesha, Chief Executive Officer of Pelthos. “This facility will be instrumental in helping us promote both ZELSUVMI and Xepi Cream to the pediatric and dermatologic communities, and assist us in further scaling our business, including the launch of the recently acquired Xeglyze.”
About Horizon Technology Finance
Horizon Technology Finance Corporation (NASDAQ: HRZN), externally managed by Horizon Technology Finance Management LLC, an affiliate of Monroe Capital, is a leading specialty finance company that provides capital in the form of secured loans to venture capital and private equity-backed companies and publicly traded companies in the technology, life science, healthcare information and services, and sustainability industries. The investment objective of Horizon is to maximize its investment portfolio’s return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. Horizon is headquartered in Farmington, Connecticut, with a regional office in Pleasanton, California, and investment professionals located throughout the U.S. Monroe Capital is a premier asset management firm specializing in private credit markets across various strategies, including direct lending, technology finance, venture debt, opportunistic, structured credit, real estate and equity. To learn more, please visit horizontechfinance.com .
About Pelthos Therapeutics
Pelthos Therapeutics is a biopharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens. The company’s lead product ZELSUVMI™ (berdazimer) topical gel, 10.3%, for the treatment of molluscum contagiosum, was approved by the U.S. Food and Drug Administration in 2024. More information is available at www.pelthos.com . Follow Pelthos on LinkedIn and X .
Forward-Looking Statements
Statements included herein may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance, condition or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in Horizon’s filings with the Securities and Exchange Commission. Horizon undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260115051163/en/
Investor Relations:
ICR
Garrett Edson
ir@horizontechfinance.com
(860) 284-6450
Media Relations:
ICR
Chris Gillick
HorizonPR@icrinc.com
(646) 677-1819
FAQ**
How will the $50 million venture loan facility provided by Horizon Technology Finance Corporation impact Pelthos Therapeutics Inc Com (New) PTHS's ability to market and expand the use of ZELSUVMI™ in treating molluscum contagiosum?
What specific growth strategies will Pelthos Therapeutics Inc Com (New) PTHS implement using the loan proceeds to promote ZELSUVMI™ alongside Xepi® Cream and Xeglyze®?
Given Horizon's expertise in financing life science companies, how does this partnership enhance Pelthos Therapeutics Inc Com (New) PTHS's position in the dermatology space?
What metrics will Pelthos Therapeutics Inc Com (New) PTHS use to measure the success of its promotional efforts for ZELSUVMI™, Xepi Cream, and Xeglyze®, following the infusion of capital from Horizon Technology Finance Corporation?
**MWN-AI FAQ is based on asking OpenAI questions about Pelthos Therapeutics Inc Com (New) (NYSE: PTHS).
NASDAQ: PTHS
PTHS Trading
-1.27% G/L:
$23.25 Last:
808 Volume:
$23.25 Open:
